Knowledge graph · Trial
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
COMPLETED
- Identifier
- CI-TRIAL-00090750
- Entity page
- /trial/NCT04082364 ↗
- Edges
- 6
- Neighbours
- 3 cancers3 drugs
- Drawn
- 6 of 6 neighbours (cap 60); table lists every fetched edge
Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.
Most connectedLung Non-Small Cell Carcinoma 3,149Malignant Colorectal Neoplasm 1,866ABL1 298EGFR 276Imatinib 450Dasatinib 321
Neighbourhood
Radial view
Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.
Edges
Every edge, grouped by relationship
Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.
| Relationship | Neighbour | Direction | Evidence level | Cancer context | Support | Claim | Source | Expand |
|---|---|---|---|---|---|---|---|---|
| Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer condition of …CONDITION_OFderived3 of 3 | ||||||||
| ← condition of | Gastric Neoplasm registry condition “Gastroesophageal Junction Cancer” mapped PROBABILISTIC | — | — | Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| ← condition of | HER2-Positive Gastric Adenocarcinoma registry condition “HER2-positive Gastric Cancer” mapped ALIAS | — | ||||||